Syn303

Syn303 is a monoclonal antibody that specifically targets misfolded and aggregated forms of **α-synuclein**, recognizing a conformational epitope spanning amino acids 1–5 of both human and mouse α-synuclein. Its primary mechanism of action is binding extracellular misfolded α-synuclein, thereby blocking the uptake and cell-to-cell spread of α-synuclein pathology. In preclinical models of Parkinson’s disease (PD), Syn303 administration reduces the propagation of pathological α-synuclein aggregates (Lewy body-like pathology), dopaminergic cell loss, and motor dysfunction. Syn303 can reach the central nervous system after intraperitoneal administration, showing effectiveness in both inhibition of transmission and reduction of established pathology.

Brand names

Syn303Syn-303Syn 303

Other names

Syn303Syn-303Syn 303